undamentalytics Newsletter
Sign in

Goodrx Holdings, Inc. key statistics and ratios

In fiscal 2025, Goodrx Holdings, Inc. had return on equity of 4.5%, an operating margin of 11.0%, debt equal to 80.3% of equity and a current ratio of 2.61. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Operating margin31.0%36.0%−50.1%1.8%0.2%−3.6%8.3%11.0%9.5%
Net margin17.6%17.0%−53.3%−3.4%−4.3%−1.2%2.1%3.8%2.1%
Free-cash-flow margin17.8%21.1%20.1%23.4%18.6%18.3%23.1%20.6%25.1%
Return on equity———−3.3%−4.0%−1.1%2.2%4.5%2.6%
Return on assets—17.1%−31.6%−1.6%−2.0%−0.6%1.1%2.2%0.9%
Asset turnover—1.000.590.480.480.470.530.570.42
Current ratio—2.5918.2413.4212.057.125.322.611.38
Debt to equity——95.8%81.1%81.9%86.2%69.0%80.3%75.1%
Interest cover (operating income ÷ interest)3.5x2.8xn/m0.6x0.1xn/m1.2x2.1x1.8x
Effective tax rate16.3%20.4%————47.9%46.2%60.7%
R&D as % of revenue17.6%7.5%11.2%16.9%18.7%18.1%15.6%15.2%14.9%
Capital spending as % of revenue0.3%0.4%3.7%0.6%0.5%0.1%0.2%0.4%0.6%
Free cash flow ÷ net income101.5%123.9%————>999%540.0%>999%
Dividends ÷ net income>999%————————
Dividends and buybacks ÷ free cash flow>999%—0.0%0.0%71.2%75.8%87.0%131.6%43.1%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

4 of 7 checks passed · June 30, 2026
What it owns · $2.3bn
Short-term assets $1.6bnLonger-term assets $744m
What it owes, and who funded it · $2.3bn
Short-term liabilities $1.2bnLonger-term liabilities $537mShareholders' equity $648m
  • Short-term assets cover short-term liabilities $1.6bn of assets due within a year against $1.2bn of liabilities due within a year.
  • Short-term assets cover long-term liabilities $1.6bn short-term assets against $537m of longer-dated liabilities.
  • More cash than debt $296m of cash against $487m of debt.
  • Debt below 40% of shareholders' equity Debt is 75% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 79% to 75% over five years.
  • A year's operating cash flow covers at least 20% of debt $202m of operating cash flow against $487m of debt.
  • Operating profit covers interest at least five times over Operating income of $75m against $41m of interest.

From Goodrx Holdings, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

28 /100

Weak moat

How hard Goodrx Holdings's competitive advantage looks for rivals to wear away, judged from 7 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -1.1% of total assets over 6 years.

  • Durability 0 / 20

    Operating margin has been a median 4.3%; its worst year was -58.1%.

  • Cash conversion 20 / 20

    Free cash flow was positive in 6 of 6 years, at a median 19.4% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (33 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: DOCS vs GDRXGDRX vs PHRGDRX vs OMCLGDRX vs WAY

More: Health Care Technology stocks compared, Health Care sector, rankings of US companies

Figures from Goodrx Holdings, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Goodrx Holdings, Inc.